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Background: Increased glucose uptake is essential for carcinogenesis.
Results: RasV12-induced epigenetic inactivation of RRAD promotes glucose uptake and tumor formation.
Conclusion: RRAD might act as a functional tumor suppressor by inhibiting glucose uptake.
Significance: Down-regulation of RRAD in tumor tissues might be associated with the Warburg effect.
RRAD (Ras-related associated with diabetes) is a small Ras-
related GTPase that is frequently inactivated by DNA methyla-
tion of the CpG island in its promoter region in cancer tissues.
However, the role of the methylation-induced RRAD inactiva-
tion in tumorigenesis remains unclear. In this study, the Ras-
regulated transcriptome and epigenome were profiled by com-
paring T29H (a RasV12-transformed human ovarian epithelial
cell line) with T29 (an immortalized but non-transformed cell
line) through reduced representation bisulfite sequencing and
digital gene expression. We found that RasV12-mediated onco-
genic transformation was accompanied by RRAD promoter
hypermethylation and a concomitant loss of RRAD expression.
Inaddition,wefoundthat theRRADpromoterwashypermethyl-
ated, and its transcription was reduced in ovarian cancer versus
normal ovarian tissues. Treatment with the DNA methyltrans-
ferase inhibitor 5-aza-2-deoxycytidine resulted in demethyla-
tion in the RRAD promoter and restored RRAD expression in
T29H cells. Additionally, treatment with farnesyltransferase
inhibitor FTI277 resulted in restored RRAD expression and
inhibited DNA methytransferase expression and activity in
T29H cells. By employing knockdown and overexpression tech-
niques in T29 and T29H, respectively, we found that RRAD
inhibited glucose uptake and lactate production by repressing
the expression of glucose transporters. Finally, RRAD overex-
pression in T29H cells inhibited tumor formation in nudemice,
suggesting that RRAD is a tumor suppressor gene. Our results
indicate that RasV12-mediated oncogenic transformation
induces RRAD epigenetic inactivation, which in turn pro-
motes glucose uptake and may contribute to ovarian cancer
tumorigenesis.
Ras, a small 21-kDa GTPase that regulates cell proliferation
and differentiation, plays a critical role in cancer initiation and
progression. Mutations in genes of the human Ras family
(H-Ras, K-Ras, and N-Ras) have been detected in 30% of
human cancers (1, 2). As a membrane protein, Ras serves as a
molecular switch that mediates signal transduction across the
membrane. Dysregulation of Ras signaling ultimately leads to
oncogenesis (1, 3–6). Although multiple Ras effectors have
been identified, the precise role of Ras in oncogenic transfor-
mation remains unclear. Dissection of Ras and other oncogene-
mediated signal transduction networks is currently incomplete,
probably due to lack of an appropriate human cancermodel (7).
Malignant epithelial carcinomas are the most common ovarian
cancers and the most lethal gynecological malignancies.
Although incidence of Rasmutationwas observed in a subset of
ovarian carcinomas (8, 9), Ras-mediated oncogenic signal
transduction pathways have only recently been characterized in
ovarian cancer (10–12).
T29 cells were derived from primary human ovarian surface
epithelial cells by stable transfection with SV40 T/t antigens
and hTERT. The immortalized but non-oncogenic T29 cells
were further transformed by introducing oncogenicHRasV12 to
generate the T29H cell line, which resembles natural ovarian
cancer in several aspects (10, 12). Functional proteomics anal-
ysis of Ras-mediated transformation in these cell lines enabled the
identification of proteins targeted by Ras that mediate cellular
metabolism,apoptosis, and themethylationpathways (10).Taking
advantage of the Ras-T29H ovarian epithelial cell model, Cheng’s
group also found that the OPCML (opioid-binding protein/cell
adhesion molecule-like) gene is epigenetically regulated by Ras in
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oncogenic transformation (11). However, the genetic and epige-
netic mechanisms underlying Ras involvement in oncogenic
transformation remain poorly understood.
80 years ago, Otto Warburg proposed that to overcome
nutrient limitations for uncontrolled cell proliferation, tumor
cells exhibit an altered metabolism characterized by elevated
aerobic glycolysis. This hypothesis is supported by the observa-
tion of increased glucose uptake in tumor cells (13, 14).
Although aerobic glycolysis is an inefficient way to generate
ATP, the ratios of ATP/ADP and ADH/NAD are high in pro-
liferating cells, especially when they are provided with an abun-
dant nutrient supply in the circulating blood (13, 15, 16).When
tumor cells undergo aerobic glycolysis, glucose is converted to
lactate and other intermediates for biosynthesis of fatty acids,
nonessential amino acids, and nucleotides (13). Numerous
studies examining cancer metabolism have revealed that the
genes involved in glycolysis are up-regulated in 70% of all
human cancers (14, 17); however, the precise mechanisms
underlying the up-regulation of aerobic glycolysis in tumor
cells remain unclear.
RRAD is a member of the Ras GTPase superfamily and was
first identified by its association with insulin resistance in type
II diabetes mellitus (18). Accumulating evidence suggests that
the RRAD promoter is hypermethylated in human cancers,
such as nasopharyngeal carcinoma, breast cancer, malignant
mesotheliomas, prostate cancer, cervical carcinoma, and lung
cancer, and its promoter hypermethylation is associated with
reduced RRAD expression in tumor tissues (19–25). Overex-
pression of RRAD in cultured adipocytes and muscle cells
shows a reduction in insulin-stimulated glucose uptake (26).
Ilany et al. (27) generated mice that overexpress RRAD in
muscle and found that on a high fat diet, the transgenic mice
developed more severe glucose intolerance than wild-type
mice due to increased insulin resistance, and there was a
further reduction in plasma triglyceride levels in the trans-
genic mice, which was associated with increased levels of
lipoprotein lipase. These observations led us to speculate
that RRAD may be involved in cancer aerobic glycolysis by
regulating glucose uptake.
DNA methylation changes are integral to all aspects of can-
cer genomics and have been shown to have important associa-
tions with gene expression (28). In this study, the Ras-regulated
transcriptome and epigenome were profiled using the RasV12-
induced human ovarian cancer model. We found that RasV12-
mediated oncogenic transformation was accompanied by
RRAD promoter hypermethylation and a concomitant loss of
RRAD expression. We also investigated the role of RRAD in
glucose uptake and the oncogenic potential of Ras in ovarian
epithelial cells.
EXPERIMENTAL PROCEDURES
Cell Culture, Transfection, and Stable Cell Lines—The
human ovarian epithelial cell lines T29 and T29H were gener-
ous gifts from Dr. Jinsong Liu (10, 12). 293T and HEK293 cells
were obtained from the American Tissue Culture Collection
(Manassas, VA). The stable cell lines T29H-G7 and T29H-G8
were established by co-transfecting T29H cells with pCMV6-
XL5 RRAD (OriGene, Rockville, MD) and pTK-hyg (10:1; Clon-
tech) followed by selection in hygromycin-containing medium
(100 g/ml). The pCMV-RasV12 plasmid was purchased from
Clontech. Plasmid transfection was performed using Lipo-
fectamine 2000 (Invitrogen) according to the manufacturer’s
instructions. RRAD overexpression in stable clones was vali-
dated by real-time RT-PCR andWestern blot. Cells weremain-
tained in high glucose Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum (FBS) and
1% penicillin-streptomycin and were cultured in an incubator
in a 5% CO2 humidified atmosphere at 37 °C.
Bisulfite Treatment and Promoter DNA Methylation
Analysis—Genomic DNA was extracted using the genomic
DNA extraction kit (TIANGEN, Beijing, China). Genomic
DNA (750 ng) is used as the startingmaterial andwas converted
by sodium bisulfite using the EZ DNA Methylation Kit (Zymo
Research, Irvine, CA). TheRRADpromoter region (5 to315
upstream of the TSS) was amplified from the modified DNA
using Nest1 and Nest2 primers. The primer sequences are as




sense). TheNest1 PCRwas performed in a total volume of 20l
using 100 ng of bisulfite-converted DNA as a template with an
initial 95 °C denaturation for 5 min, followed by 32 cycles of
1-min denaturation at 95 °C, 30-s annealing at 56 °C, and 45-s
extension at 72 °C. The Nest2 PCR was performed in a total
volume of 35 l containing 4.5 l of the 10-fold diluted Nest1
PCR product under the same PCR conditions for 36 cycles. The
PCR product was gel-purified, ligated into pGEM-T (Promega,
Madison, WI), sequenced, and analyzed with the PUMA soft-
ware program.
HumanOvarianCancer andNormal Specimens—42ovarian
tumors and 10 normal tissues were collected from subjects who
underwent surgery in TheGeneral Hospital of the People’s Lib-
eration Army (Beijing, China). Informed consent was obtained
from all subjects. The protocol was approved by the Scientific
Ethics Committees of TheGeneral Hospital of the People’s Lib-
eration Army. All ovarian tumors and control tissues were con-
firmed by the hospital’s clinical pathology department. The
classification and features of the ovarian tissueswere as listed in
Tables 1 and 2. None of the patients received chemotherapy
before surgery. Tissue samples were frozen immediately in liq-
uid nitrogen and stored at80 °C.
Demethylation Treatment with 5-aza-dC3—T29H cells were
placed in a 10-cm plate, incubated to 50% confluence, and then
treated with 5-aza-dC. Growth medium was changed every
24 h. Cells were harvested after 4 days for RNA and DNA
extraction, which was carried out using the TIANGEN kit
(Beijing, China). The extracted RNA and DNA were then
used for RRAD expression and promoter methylation anal-
ysis, respectively. Differences were analyzed by the paired t
test using SPSS version 17.0 software. All samples were nor-
malized to -actin.
3 The abbreviations used are: 5-aza-dC, 5-aza-2-deoxycytidine; RRBS-seq,
reduced representation bisulfite sequencing; DNMT, DNA methytrans-
ferase; DGE, digital gene expression; DMR, differential methylation region.
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RNA Interference—T29 or T29H cells were seeded in 6-well
plates at 2.5 105 cells/well 1 h before transfection with siRNA
and siPORTTM NeoFXTM agent (Invitrogen) according to the
manufacturer’s instructions. The cells were collected 72 h later.
The small interfering RNAs siRRAD and the negative control
siCONTwere obtained from Invitrogen.HRasV12 siRNAs were
purchased from Ambion (Austin, TX).
Real-time Reverse Transcription PCR (RT-PCR)—RNA was
prepared using TRIzol reagent (Invitrogen) and treated with
RNase-free DNase I (Fermentas, Glen Burnie, MD) for 30 min.
The DNA-free RNA was reverse-transcribed using the Molo-
ney murine leukemia virus reverse transcription kit (Promega,
Madison, WI). A sample prepared in the absence of reverse
transcriptase served as a negative control. SYBR Green real-
time PCR was performed on an ABI PRISM 7300 sequence
detection system (Applied Biosystems). Differences between
samples were analyzed by independent sample t test using SPSS
version 17.0 software. All samples were normalized to -actin.
The primer sequences for the glucose transporter have been
described previously (29). The sequences of other primers used
are listed in Table 3.
Western Blotting—Cells were collected and lysed as described
(20). Lysates (80g) were separated by SDS-PAGE and immuno-
blottedwithanti-RRADantibody (Sigma).-Actinwasusedas the
loading control.
DNA Methytransferase (DNMT) Activity Assay—The nuclear
extractswerepreparedusing theNuclear Extraction kit (Epigen-
tek), and then aliquotted and stored at 80 °C until the assay
was performed. DNMT activity was measured using the
DNMT Activity/Inhibition Assay Ultra kit (Epigentek), as
described previously (30, 31). Briefly, 5-g nuclear extracts for
each assay were used as the start material, and the procedure
was according to the manufacturer’s instructions.
Glucose Uptake—Glucose uptake was determined as the
accumulation of 2-deoxy-D-[3H]glucose (PerkinElmer Life Sci-
ences). Briefly, cells were rinsed twice with PBS and incubated
with insulin at 37 °C for 30 min. The cells were washed twice
againwith PBS and incubatedwith 2-deoxy-D-[3H]glucose (200
M in PBS, 1 Ci/well) at 37 °C for 15 min. Cytochalasin B was
used as a negative control. The reaction was terminated with
three rapidwashes in ice-cold PBS. The cells were lysedwith 1%
SDS and prepared for scintillation counting (MicroBeta-1450,
PerkinElmer Life Sciences). Differences between samples were
TABLE 1
































1 57 s III W 1 63
2 73 s III M 2 55
3 55 s III M 3 48
4 64 s III M 4 46
5 55 s III M 5 47
6 54 s III M 6 52
7 54 s III M 7 55
8 53 s III M 8 45
9 52 s I P 9 52
10 48 s II P 10 56
11 37 s III P
12 55 s III P
13 53 s III P
14 58 s III P
15 45 s III P
16 53 s III P
17 68 s III P
18 58 s III P
19 38 s IV P
20 56 s IV P
21 40 s IV P
22 53 s III W
23 67 s III M
24 50 s III M
25 50 s III P
26 65 s III M
27 52 s III M
28 58 s IV P
29 47 s III W
30 57 s III P
31 63 s III P
32 62 m III P
33 47 m II W
34 48 m I W
35 47 m I W
36 66 m III W
37 64 e II M
38 78 e III M
39 66 e IV P
40 51 e II P
41 51 o I P
42 51 o IV P
a s, serous; m, mucinous; e, endometrioid; o, others.
bW, well; M, moderately; P, poorly.
TABLE 3
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analyzed by independent sample Student’s t test using SPSS
version 17.0 software.
Lactate Production—Lactate was quantified as described
previously (32). Briefly, overnight cultures were harvested and
resuspended in phosphate buffer containing 1 mM EDTA and
sonicated to disrupt the cells. The cell debris was removed,
and serial dilutions of the suspension were assayed for lactate,
using the lactate assay kit from BioVision (Milpitas, CA). Lac-
tate production was normalized to cell number. Differences
between samples were analyzed by independent sample t test
using SPSS version 17.0 software.
Library Preparation and Sequencing of RRBS-seq—RRBS
libraries were constructed for T29 and T29H cell lines, as
described previously (33). Briefly, 500 ng of genomic DNA was
digestedwith 20 units ofMspI (NewEnglandBiolabs) in a 20-l
reaction for 20 h at 37 °C. After purification, the digested prod-
ucts were blunt-ended, and then dA was added, followed by
methylated adapter (Illumina) ligation. To obtain DNA frac-
tions in the 40–120 and 120–220 bp range of MspI-digested
products, two ranges (160–240 and 240–340 bp) of adapter-
ligated fractions were excised from 2% agarose gel. The size-
selected DNA was bisulfite-treated for two rounds using the
EpiTect bisulfite kit (Qiagen, Venlo, The Netherlands) follow-
ing the manufacturer’s standard protocol. The final libraries
were generated by amplification with HiFi HotStart Uracil
ReadyMix (Kapa Biosystems, Boston, MA), and Illumina Mul-
tiplexing PCRPrimers. The quality and quantity of RRBS librar-
ies were analyzed by an Agilent 2100 Bioanalyzer (Agilent
Technologies, Santa Clara, CA) and RT-PCR, respectively.
Finally, Illumina HiSeq 2000 was used to sequence the libraries
according to the manufacturer’s protocol.
RRBS-seq Data Analysis—For sequencing reads produced by
HiSeq 2000, the low quality reads and adapter sequences were
first removed from the raw reads. The quality of resulted clean
reads was checked by FastQC (available on the World Wide
Web). All bisulfite-treated short reads and human reference
genome sequence were then converted to three-letter alphabet.
The software SOAP2 (34) was used for the alignment of the
transformed reads to the transformed reference genome
sequence with twomismatches allowed in the seed (40 bp) (35).
To identify the position ofmethylcytosines and themethylation
pattern of each methylcytosine, BSMAP was used to process
the alignment results to identify the methylcytosines where at
least three reads were covered. The detailed annotation of methyl-
cytosines was performed using RRBS-Analyzer software (36).
The cytosine methylation pattern in CpG islands across T29
and T29H sequences was determined from the mapping reads
of each sample. Based on the CpG methylation pattern, the
differential methylation regions (DMRs) were then identified
by RRBS-Analyzer (supplemental Table S1). Two biological
replicates were carried out for each cell line, and about 3.50-
and 4.40-Gb 100-bp paired-end data were generated for T29
and T29H in each replicate, respectively, of which about 80%
can be uniquely mapped to the human genome (supplemental
Table S2). The efficiency of bisulfite treatmentwas evaluated by
calculating the C to T conversion rate for all cytosines in the
CpH context (CpA, CpC, or CpT dinucleotides). It was shown
that the bisulfite conversion rates of both libraries were at least
99.80% even if we assumed that all 5mC in CpH dinucleotides
were due to conversion failure, whichmaintained the false pos-
itive rate below 0.5%. In addition, we observed that the Pearson
correlations were about0.95 within intrareplicate from both
cell lines, indicating the high quality of our RRBS procedures
(data not shown).
DGE Library Preparation and Sequencing—DGE libraries
from both T29 and T29H cells were prepared by using the Illu-
minaGene Expression Sample Prep kit. Briefly, mRNA for each
sample was reverse-transcripted to cDNA. Then the resulting
cDNAs were ligated to sequencing adapters, and the products
were purified and enriched with PCR to create the final cDNA
libraries, which were then sequenced using the Illumina GAII
System.
DGE Data Analysis—The raw data were initially filtered by
removing adapters, empty reads, and low quality tags. All clean
tagswere thenmapped to the human reference sequences using
Bowtie (37) with a maximum 1-bp mismatch allowed. The
clean tags that mapped to multiple sites of reference sequences
were filtered, and the remaining clean tags were designated as
unambiguous clean tags. The number of unambiguous clean
tags for each gene was calculated and then normalized to num-
ber of transcripts per million clean tags (38). To compare the
gene expression between T29 and T29H cells statistically, the
false discovery rate was used to determine the statistical signif-
icance in multiple tests. An absolute value of the log2 ratio1
and a false discovery rate0.0001 were used as the thresholds
to determine significant differences in gene expression (39).
The differentially expressed genes were chosen for the KEGG
pathway and GO enrichment analyses by using the ClueGO
plugin in Cytossape. A Bonferroni corrected p value of 0.05
based on right-sided hypergeometric tests was selected as the
threshold for significant pathway/GO enrichment of the gene
sets.
Tumor Growth Assay—All animal experiments were
approved by the Animal Care and Use Committee at the Insti-
tute of Psychology, Chinese Academy of Sciences (Beijing,
China) and were conducted in accordance with the standard
animal operating procedures by following the animal welfare
guidelines. Cells (2.5  106; T29H-G7, T29H-G8, T29, and
T29H) were harvested and resuspended in 0.1 ml of PBS. The
suspensions were then injected subcutaneously into the
abdomen of 5-week-old male nude mice. Each treatment
group contained five mice. Tumors were measured with cal-
ipers in three dimensions once a week. The entire experi-
ment was halted 6 weeks later when all T29H-injected mice
had a visible tumor (15 mm) in a single dimension. Differ-
ences between groups of cells or between sets of in vitro
experiments were analyzed by one-way analysis of variance
and then by Student’s t test.
Statistical Analysis—Expression differences in clinical tissue
samples were analyzed by the non-parametric Mann-Whitney
U test, using SPSS version 17.0 software. Data are displayed as
means 	 S.E. Statistical significance was accepted at p  0.05
when compared with the corresponding control or as specifi-
cally indicated.
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RRADDNAMethylation Is Inversely Correlated with Expres-
sion in Cultured Ovarian Cell Models—To profile the Ras-reg-
ulated epigenome, we performed RRBS-seq, which allows
quantitative measurement of the DNA methylation levels at
single-base resolution in the T29 and T29H cell lines. It was
revealed that our RRBS-seq data have covered 14.17 and 14.90%
of all of the 56.33 million CpG in the whole human genome for
T29 and T29H, respectively. For the CpG locating in the CpG
islands, 46.91 and 47.35% of them have been covered.
DNA methylation changes within the promoter region of a
given gene are likely to regulate its expression level. We then
measured the mRNA expression profiles of T29 and T29H
using the DGE method (40). Initially, a total of 6,341,442 and
5,747,842 raw sequence reads were produced for T29 and
T29H, respectively. To determine the expression level of each
gene, the counts of reads aligned to the human genome were
calculated and normalized by the total reads of each cell line
and standardized to reads permillion. In comparison with T29,
1,963 differentially expressed genes, including 1,354 up-regu-
FIGURE 1. RRAD DNAmethylation is inversely correlated with expression in cultured ovarian epithelial cells. A, starburst plot showing the association
betweenDMRs in the promoter and the gene expression level. B, detailed viewofDMRof RRAD from the RRBS-seqdata.C, DNAmethylation status of the RRAD
promoter in T29 and T29H cells (***, p 0.001). D, reduced RRADmRNA levels in T29H versus T29 cells. E, reduced RRAD protein levels in T29H cells. Data are
shown as means	 S.E. (error bars) (**, p 0.01); -actin was used as an internal control.
Oncogenic Transformation Represses RRAD Expression
MAY 16, 2014•VOLUME 289•NUMBER 20 JOURNAL OF BIOLOGICAL CHEMISTRY 14229











lated genes and 609 down-regulated genes, were identified in
T29H with at least 2-fold differences in expression level and false
discovery rate value less than 0.0001 (supplemental Table S3). In
addition, functional annotation of differentially expressed genes
showed that they are enriched inmultiple pathways (supplemen-
tal Table S4), most of which are involved in cancer and metab-
olism, including focal adhesion pathway (hsa04510), ribosome
pathway (hsa03010), MAPK signaling pathway (hsa04010),
PI3K-Akt signaling pathway (hsa04151), VEGF signaling path-
way (hsa04370), and pathways in cancer (hsa05200), ECM-re-
ceptor interaction (hsa04512), glycosaminoglycan biosynthesis
(hsa00532), and N-glycan biosynthesis (hsa00510). Our data
suggest that Ras transformation affects diversified cancer-re-
lated signaling, which may contribute to the carcinogenesis of
ovarian cancer.
Subsequently, we investigated the association between DNA
methylation and gene expression by integrating the differen-
tially expressed genes and DMRs occurring in the promoter
FIGURE 2. RRAD promoter methylation is inversely correlated with expression in epithelial ovarian carcinoma. A, methylation status of the RRAD
promoter region in normal tissues and epithelial ovarian carcinoma. Each filled bar represents the percentage of DNAmethylation per CpG site, and the open
bar represents the percentage of demethylated CpG at each corresponding site (**, p
 0.0045). B, overall comparison of relative RRADmRNA levels in ovarian
cancer (n
 42) and normal tissues (n
 10). Data are shown as means	 S.E. (error bars) (*, p 0.05, Mann-Whitney U test). C, RRADmRNA levels in individual
cancer tissues and the reference tissue sample, which was mixed from 10 normal tissues.
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FIGURE 3.Demethylation of RRAD in T29H by 5-aza-dC results in RRADgene derepression. A, DNAmethylation status of the RRAD promoter in 5-aza-dC-
treated T29H cells. The red boxmarks the “hot spots” that are demethylatedupon5-aza-dC treatment (*,p
 0.027). B, relativeRRADmRNA levels after 5-aza-dC
treatment. C, RRAD protein levels after treatment with 20M 5-aza-dC.D, DNMTmRNA levels in T29H. E, relative DNMTmRNA levels after FTI277 treatment. F,
relative DNMT activity following FTI277 treatment.G, relativemRNA levels of RRAD following FTI277 treatment.-Actinwas used as a loading control. Data are
shown as means	 S.E. (error bars) (*, p 0.05; **, p 0.01; ***, p 0.001).
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(Fig. 1, A and B). Interestingly, we observed that the expression
level of the RRAD gene was inversely correlated with DNA
methylation level most significantly. In comparison with T29,
the RRAD promoter region was3.9-fold increased in methyl-
ation level and7.5-fold decreased in gene expression level in
T29H. By employing the bisulfite sequencing and RT-PCR, we
confirmed that the RRAD CpG island in the promoter was
highly methylated in T29H cells and hypomethylated in T29
cells (Fig. 1C). Consistent with these results, RRADmRNA and
its encoded protein levels were dramatically reduced in T29H
versus T29 by 20-fold (Fig. 1, D and E).
Epigenetic Inactivation of RRAD in Human Ovarian Cancer
Tissues—We then characterized the RRAD promoter methyla-
tion status and the expression level in 42 human ovarian can-
cers and 10 normal ovarian tissues. As shown in Fig. 2A, RRAD
promoter methylation was significantly increased in ovarian
cancer versus normal ovarian tissues (p
 0.0045). The overall
RRAD transcript levels were significantly reduced in tumor ver-
sus normal ovarian tissues (Fig. 2B). Because corresponding
normal tissue could not be obtained from these 42 cancer
patients, RRAD transcription was quantified in a mixture of 10
normal ovarian tissues and used as the reference (41). As shown
in Fig. 2C, the majority (32 of 42) of the cancer tissues tested
showed dramatically reduced RRAD transcription compared
with that in the normal ovarian tissues. These observations sug-
gest that RRAD is epigenetically inactivated in ovarian cancer
tissues.
RasV12-mediated Oncogenic Transformation Induces Pro-
moter Hypermethylation and Represses RRAD Expression—To
confirm that RRAD down-regulation in T29H cells was due to
promoter hypermethylation, we treated T29H cells with the
demethylating agent 5-aza-dC. Indeed, our results revealed that
several “hot spots” in the RRAD promoter could be remarkably
demethylated (at 68, 76, and 86 bp in our bisulfite sequencing
region, Fig. 3A). Simultaneously, RRAD transcription and its pro-
tein levels were dramatically increased (Fig. 3, B and C). These
results suggest that promoter hypermethylation represses RRAD
expression in T29H cells. Moreover, the expression and activity
inDNMTswere significantly increased inT29Hcells compared
with in T29 cells via RT-PCR and theDNMTactivity assay (Fig.
3,D and F). Consistently, treatmentwith FTI-277, a specific Ras
inhibitor, down-regulated the mRNA levels (Fig. 3E) and activ-
ities (Fig. 3F) of DNMTs, which was concomitant with an up-
regulation of RRAD expression (Fig. 3G).
T29H cells are derived from T29 cells by introducing an
oncogenic HRasV12. To exclude the possibility that the differ-
ence in promoter methylation and expression of RRAD is due
to clonal variation, we transiently transfected T29 cells with
pCMV-RasV12. As expected, RRAD transcript and protein lev-
els were dramatically reduced upon overexpression of HRasV12
in comparison with the empty vector control by more than
3-fold (Fig. 4, A–C). A similar effect was observed in other cell
lines (data not shown). In addition, Ras knockdown in T29H
increased RRAD expression (Fig. 4, D–F).
RRADDown-regulates Glucose Uptake and Lactate Production—
In contrast to normal differentiated cells, which primarily rely
on mitochondrial oxidative phosphorylation to generate the
energy needed for cellular processes, most cancer cells rely on
aerobic glycolysis, a phenomenon termed “theWarburg effect”
(13). Aerobic glycolysis, which breaks down glucose to lactate,
FIGURE 4. RRAD expression is regulated by HRasV12. A–C, overexpression of HRasV12 in T29 cells. A,HRasV12 transfection efficiency in T29 cells, measured by
real-timeRT-PCR.B andC, reducedprotein (B) andmRNA (C) levels of RRAD inHRasV12-overexpressing T29 cells.D–F, siRNAknockdownofHRasV12 in T29Hcells.
D, transfection efficiency of HRasV12 siRNA in T29H cells. E and F, up-regulation of RRAD in HRasV12 knockdown T29H cells. E, protein level; F, relative RRAD
transcript level. Data are shown as means	 S.E. (error bars) (**, p 0.01).
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is an inefficient way to generate ATP. In general, cancer cells
consume more glucose than normal cells to generate sufficient
amounts of ATP, and increased glucose uptake and lactate pro-
duction are hallmarks of cancer cells (13, 14). Therefore, we
measured glucose uptake and lactate production in T29 and
T29H cells. Our results revealed that RasV12-mediated onco-
genic transformation led to an increase in glucose uptake and
lactate production (Fig. 5A).
Previous studies have shown that overexpression of RRAD in
cultured adipocytes andmuscle cells results in diminished insu-
lin-stimulated glucose uptake (26), and overexpression of
RRAD in muscle tissues of transgenic mice worsens diet-in-
duced insulin resistance and glucose intolerance and reduces
plasma triglyceride levels (27). We speculated that increased
glucose uptake and lactate production are the consequences
of RRAD down-regulation. To test this hypothesis, we
knocked down RRAD in T29 cells and found that glucose
uptake and lactate production were significantly increased
(Fig. 5, B–D). Accordingly, overexpression of RRAD in T29H
cells, which express relatively low levels of RRAD, led to a
significant decrease in glucose uptake and lactate produc-
tion (Fig. 5, E–G), suggesting that RRAD negatively influ-
ences aerobic glycolysis.
RRAD Suppresses the Expression of Glucose Transporters—
Insulin positively regulates glucose uptake by inducing the
expression of glucose transporters (42) and may also up-regu-
late RRAD (43, 44). Therefore, we addressed whether RRAD
regulates the expression of glucose transporters. As shown in
Fig. 6A, the expression levels of most glucose transporters were
decreased in RRAD-overexpressing T29H cells. Consistent
with the observation that RRAD was down-regulated in
T29H cells as compared with T29 cells, we found that the
expression levels of most glucose transporters were increased
in T29H cells as compared with T29 cells (Fig. 6B). These
results suggest that increased glucose consumption in
RasV12-transformed ovarian epithelial cells is probably the conse-
quenceof up-regulationof glucose transporters inducedbydown-
regulation of RRAD.
Overexpression of RRAD in T29H Cells Represses the Onco-
genic Potential of RasV12—Aerobic glycolysis in cancer cells
may facilitate the uptake and incorporation of nutrients into
the biomass that are necessary for producing a newcell (13).We
FIGURE 5. RRAD inhibits glucose uptake and lactate production in ovarian epithelial cells. A, reduced glucose uptake and lactate production in T29 cells
versusT29Hcells that express lower levels ofRRAD.B–D, increasedglucoseuptakeand lactateproduction in siRRAD knockdownT29cells.B, relativeglucoseand
lactate levels.C, relativeRRAD transcript level.D, RRADprotein expression level. E–G, significantly decreasedglucoseuptake and lactate productionuponRRAD
overexpression in T29Hcells. E, relativeglucose and lactate levels. F, relativeRRAD transcript level.G, RRADprotein expression level. Data aremeans	 S.E. (error
bars) (*, p 0.05; **, p 0.01).
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demonstrated that RasV12-mediated oncogenic transformation
increased glucose uptake and lactate production by down-reg-
ulating RRAD expression. Therefore, RRAD derepression may
inhibit the oncogenic potential of RasV12. To test this hypothe-
sis, we generated two stable RRAD-overexpressing T29H cell
lines, T29H-G7 andT29H-G8 (Fig. 7,A andB). As shown in Fig.
7C, glucose uptake and lactate production were inhibited in
RRAD-overexpressing versus control T29H cells. We then
inoculated T29, T29H, T29H-G7, andT29H-G8 cells into nude
mice to examine the effect of RRAD on tumor formation. As
reported previously (12), no tumors were observed in mice
injected with T29 cells. However, tumor size was significantly
smaller in mice inoculated with T29H-G7 and T29H-G8 cells
than that in T29H-injected mice (Fig. 7, D–F). These results
indicated that overexpression of RRAD in T29H cells inhibited
the oncogenic potential of RasV12.
DISCUSSION
Using a well defined human ovarian cancer model, we
have demonstrated that RRAD expression was lower in
T29H than in T29 cells due to promoter hypermethylation
(Fig. 1). Knockdown of RasV12 in T29H cells resulted in up-
regulation of the RRAD gene (Fig. 4). In addition, we found
that DNMTs were up-regulated by RasV12 and that treat-
ment with FTI-277, a specific Ras inhibitor, led to down-
regulation of DNMTs in T29H cells (Fig. 3). Taken together,
our data suggest that activation of the Ras pathway up-reg-
ulates the expression of DNMTs, and Ras-responsive tran-
scription factors may recruit DNMTs to the RRAD promoter
to induce DNA methylation.
We demonstrated that RRAD inhibited glucose uptake in
ovarian epithelial cells (Fig. 5). Consistently, we showed that
RRAD repressed lactate production. In addition, we showed
that RRAD suppressed the expression of glucose transporters.
Previous studies have demonstrated that RRAD is associated
with calmodulin-dependent protein kinase II, cAMP-depen-
dent protein kinase (PKA), protein kinase C (PKC), and casein
kinase II and is phosphorylated by these protein kinases (45,
46). Interestingly, most of these protein kinases are involved in
glucose metabolism. Activation of PKA and PKC increased the
activity of the Na-glucose cotransporter SGLT2 (47), and cal-
modulin-dependent protein kinase II positively regulates glu-
cose uptake by affecting the GLUT4 (glucose transporter 4)
expression level (48, 49). Therefore, it is tempting to speculate
that RRADmay function downstream for these protein kinases
and repress glucose uptake by inhibiting the expression or
activities of glucose transporters.
It has been postulated that proliferating and cancer cells
could choose glycolysis to efficiently prepare nutrients for fast
cell growth (13, 14). Hirabayashi et al. (50) reported that a car-
bohydrate-rich diet promoted Ras/Src-mediated transforma-
tion in Drosophila and that transformed tumor tissues exhibit
diet-mediated insulin sensitivity, increased glucose uptake
activity, and resist apoptosis. They also demonstrated that acar-
bose and AD81 induce tumor cell apoptosis by targeting glu-
cose uptake and Ras/Src AD81, respectively (50). We showed
here that RasV12-transformed T29H cells could take up more
glucose due to RRAD down-regulation, and overexpression of
RRAD in T29H cells inhibited glucose uptake and hence
reduced glycolysis (Fig. 5), which displayed a disadvantage for
tumor growth. Consistent with this, we found that two stable
RRAD-overexpressing T29H cells, T29H-G7 and T29H-G8,
took up less glucose and produced less lactate than those
T29H did (Fig. 6, A–C). In addition, they formed smaller
tumors after injection into nude mice (Fig. 6, D–F). Consid-
ering that RRAD inhibited cell migration in vascular smooth
muscle cells (51) and lung cancers (25) and that disruption of
RRAD resulted in cell cycle arrest and senescence (20, 52),
we propose that RRAD is a tumor suppressor gene, which
may be a potential new anti-tumor target through regulating
RRAD activity.
We also found that RRAD was epigenetically inactivated in
ovarian cancer tissues (Fig. 2). The fact that the Ras mutation is
found only in a certain subset of ovarian cancers (53) and30%
of other human cancers (1, 2) suggested that Ras mutation was
not the only cause for RRAD epigenetic inactivation in cancer.
Indeed, Hsiao et al. recently demonstrated that RRAD was a
direct transcriptional target of p53 and that activation of p53
leads to up-regulation of RRAD (25). Considering the fact that
p53 is frequently mutated in cancer cells, we speculate that loss
of p53 function is another cause for RRAD down-regulation in
tumor tissues. Further efforts should investigatewhethermuta-
tion of other tumor suppressor genes or oncogenes regulates
RRAD expression.
Additionally, we present the first methylome induced by
oncogenic Ras through RRBS-seq analysis. 7,567 DMRs were
FIGURE 6. Glucose transporter expression in T29, T29H, and RRAD-over-
expressing T29H cells. A, T29H cells were transfectedwith pCMV6-XL5 RRAD
or pcDNA3.1, and the levels of glucose transporters were determined by real-
time RT-PCR 48 h after transfection. B, real-time RT-PCR quantification of glu-
cose transporters in T29 and T29H cells. Data are means 	 S.E. (error bars)
(*, p 0.05; **, p 0.01).
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identified (2 test, p 0.01, Fold change 2) between T29 and
T29H through comparison of themethylation levels.We found
1,737 genes, of which promoters were overlapped with DMRs.
ClueGO analysis revealed that those genes were enriched in
multiple pathways (Table 4), such as the neuroactive ligand-
receptor interaction pathway (hsa04080), the calcium signaling
pathway (hsa04020), the o-glycan biosynthesis pathway
(hsa00512), the melanogenesis pathway (hsa04916), the basal
cell carcinoma pathway (hsa05217), the fructose and mannose
metabolism pathway (hsa00051), the Wnt signaling pathway
(hsa04310), the MAPK signaling pathway (hsa04010), the
hedgehog signaling pathway (hsa04340), and pathways in can-
cer (hsa05200; Table 5). Most of them were related to cancer
and metabolism. Some of these pathways were reported in
ovarian cancers byHuang et al. (54). Further, the comparison of
the methylation level between T29 and T29H revealed that
T29Hhad slight decrease in themethylation level of C andCpG
(Fig. 8A), which has been confirmed by the global DNA meth-
ylation analysis by the LC-MS/MSmethod (Fig. 8B). The global
hypomethylated status in T29H cells was consistent with pre-
vious studies in cancers (55), and it further indicated that T29H
is a well defined model for human ovarian cancer study.
In summary, we showed that RasV12-mediated oncogenic
transformation caused epigenetic inactivation of the RRAD
gene and that down-regulation of RRAD led to an increase in
glucose uptake, which may be associated with the unique
FIGURE 7. RRAD reduces ovarian tumor growth in vivo. A, relative RRAD transcript levels in T29H and its stable RRAD-overexpressing derivatives G7 and G8.
B, RRAD protein expression in T29H and its stable RRAD-overexpressing derivatives. C, reduced lactate production in stable RRAD-overexpressing T29H
derivatives.D, representative images ofmice in T29/T29Hmousemodels 6weeks after subcutaneous injection. T29 did not formvisible tumors; however,mice
injected with T29H, T29H-G7, T29H-G8 all formed visible tumors. Due to image quality, images of only 3 mice per treatment are shown. E, quantification of
tumor volume from subcutaneous injected athymic nude mice, n
 5. F, representative images of autopsied tumors from T29H, G7, and G8 subcutaneously
injected athymic nude mice. Data are means	 S.E. (error bars) (**, p 0.01).
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metabolic feature of tumor cells, aerobic glycolysis. Overex-
pression of RRAD in RasV12-transformed ovarian epithelial
cells repressed their oncogenic potential. Therefore, our
results suggest that down-regulation of RRAD confers
advantages to the proliferation of RasV12-transformed ovar-
ian epithelial cells.
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